Differential Augmentation of in Vivo Natural Killer Cytotoxicity in Normal Primates with Recombinant Human Interleukin-1 and Granulocyte-macrophage Colony-stimulating Factor

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1990 Mar 1

PMID 2180599

Authors

T A Davis

R L Monroy

R R Skelly

R E Donahue

T J MacVittie

Affiliations

Soon will be listed here.

Abstract

The effect of recombinant human interleukin-1 (IL-1) alpha, granulocyte-macrophage colony-stimulating factor (GM-CSF), and combined factor therapy (CFT) on Rhesus monkey peripheral blood natural killer (NK) activity in vivo was compared. During a 14-day treatment period, IL-1-treated animals demonstrated a 170% increase in NK activity against K562 target cells by day 4, reaching maximal levels (300%) at day 16, and returning to baseline by day 30. NK activity of GM-CSF-treated monkeys increased slightly (60-100%) during days 4-12, as did saline-treated monkeys, but returned to baseline values by day 16. A delayed increase in NK activity resulted after GM-CSF treatment, reaching a peak (260%) on day 23 and remaining elevated through day 39. CFT resulted in a bimodal response pattern, with two peaks of NK activity: one at day 16 and a second at day 39. The first peak of activity (223%) was significantly less than the activity attained with IL-1 alone; the second peak (300%) was of greater duration and occurred later than the peak observed in GM-CSF-treated monkeys. Unlike IL-1, GM-CSF treatment did not lead to a immediate stimulation of NK activity; augmentation was delayed by more than 7 days post treatment. CFT results suggest that GM-CSF reduced the direct NK response to IL-1; while IL-1 led to an enhanced delayed NK response. Therefore, IL-1 and GM-CSF augment NK activity through different but interrelated pathways.

References

Brandt S, Peters W, ATWATER S, Kurtzberg J, Borowitz M, Jones R . Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988; 318(14):869-76. DOI: 10.1056/NEJM198804073181401. View

Vadhan-Raj S, Keating M, Lemaistre A, Hittelman W, McCredie K, Trujillo J . Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med. 1987; 317(25):1545-52. DOI: 10.1056/NEJM198712173172501. View

Cuturi M, Anegon I, Sherman F, Loudon R, Clark S, Perussia B . Production of hematopoietic colony-stimulating factors by human natural killer cells. J Exp Med. 1989; 169(2):569-83. PMC: 2189209. DOI: 10.1084/jem.169.2.569. View

Brooks B, Rees R . Human recombinant IL-4 suppresses the induction of human IL-2 induced lymphokine activated killer (LAK) activity. Clin Exp Immunol. 1988; 74(2):162-5. PMC: 1541809. View

Gallagher G, WILCOX F, Al-Azzawi F . Interleukin-3 and interleukin-4 each strongly inhibit the induction and function of human LAK cells. Clin Exp Immunol. 1988; 74(2):166-70. PMC: 1541800. View

McIntosh J, Jablons D, Mule J, Nordan R, Rudikoff S, Lotze M . In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice. J Immunol. 1989; 143(1):162-7. View

Luger T, Krutmann J, Kirnbauer R, Urbanski A, Schwarz T, Klappacher G . IFN-beta 2/IL-6 augments the activity of human natural killer cells. J Immunol. 1989; 143(4):1206-9. View

Smith K, Lachman L, Oppenheim J, Favata M . The functional relationship of the interleukins. J Exp Med. 1980; 151(6):1551-6. PMC: 2185867. DOI: 10.1084/jem.151.6.1551. View

Welsh R . Natural cell-mediated immunity during viral infections. Curr Top Microbiol Immunol. 1981; 92:83-106. DOI: 10.1007/978-3-642-68069-4_6. View

10.

Herberman R, Ortaldo J, Mantovani A, Hobbs D, Kung H, Pestka S . Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. Cell Immunol. 1982; 67(1):160-7. DOI: 10.1016/0008-8749(82)90208-8. View

11.

Hansson M, Beran M, Andersson B, Kiessling R . Inhibition of in vitro granulopoiesis by autologous allogeneic human NK cells. J Immunol. 1982; 129(1):126-32. View

12.

Dempsey R, Dinarello C, Mier J, Rosenwasser L, Allegretta M, Brown T . The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol. 1982; 129(6):2504-10. View

13.

Kasahara T, Djeu J, Dougherty S, Oppenheim J . Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor. J Immunol. 1983; 131(5):2379-85. View

14.

Mangan K, Hartnett M, Matis S, Winkelstein A, Abo T . Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood. 1984; 63(2):260-9. View

15.

Dinarello C . Interleukin-1. Rev Infect Dis. 1984; 6(1):51-95. DOI: 10.1093/clinids/6.1.51. View

16.

Scala G, Allavena P, Djeu J, Kasahara T, Ortaldo J, Herberman R . Human large granular lymphocytes are potent producers of interleukin-1. Nature. 1984; 309(5963):56-9. DOI: 10.1038/309056a0. View

17.

Degliantoni G, Murphy M, Kobayashi M, Francis M, Perussia B, Trinchieri G . Natural killer (NK) cell-derived hematopoietic colony-inhibiting activity and NK cytotoxic factor. Relationship with tumor necrosis factor and synergism with immune interferon. J Exp Med. 1985; 162(5):1512-30. PMC: 2187923. DOI: 10.1084/jem.162.5.1512. View

18.

Savary C, Lotzova E, Gray K, Jardine J . Natural killer cell-mediated antitumor reactivity of rhesus monkeys. Nat Immun Cell Growth Regul. 1985; 4(6):328-39. View

19.

Shirakawa F, Tanaka Y, Eto S, Suzuki H, Yodoi J, Yamashita U . Effect of interleukin 1 on the expression of interleukin 2 receptor (Tac antigen) on human natural killer cells and natural killer-like cell line (YT cells). J Immunol. 1986; 137(2):551-6. View

20.

Braakman E, van Tunen A, Meager A, Lucas C . IL-2- and IFN gamma-enhanced natural cytotoxic activity: analysis of the role of different lymphoid subsets and implications for activation routes. Cell Immunol. 1986; 99(2):476-88. DOI: 10.1016/0008-8749(86)90255-8. View